Alexandria Real Estate Equities, Inc.

NYSE:ARE Stock Report

Market Cap: US$17.2b

Alexandria Real Estate Equities Valuation

Is ARE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ARE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ARE ($97.8) is trading below our estimate of fair value ($174.23)

Significantly Below Fair Value: ARE is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ARE?

Key metric: As ARE is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ARE. This is calculated by dividing ARE's market cap by their current earnings.
What is ARE's PE Ratio?
PE Ratio60.8x
EarningsUS$282.55m
Market CapUS$17.19b

Price to Earnings Ratio vs Peers

How does ARE's PE Ratio compare to its peers?

The above table shows the PE ratio for ARE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average41.7x
DOC Healthpeak Properties
45.3x-21.8%US$14.3b
OHI Omega Healthcare Investors
29.1x9.9%US$10.5b
CTRE CareTrust REIT
50.8x45.3%US$5.1b
SBRA Sabra Health Care REIT
41.5x19.2%US$4.0b
ARE Alexandria Real Estate Equities
60.5x18.5%US$17.2b

Price-To-Earnings vs Peers: ARE is expensive based on its Price-To-Earnings Ratio (60.5x) compared to the peer average (46.1x).

Price to Earnings Ratio vs Industry

How does ARE's PE Ratio compare vs other companies in the Global Health Care REITs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
ARE 60.8xIndustry Avg. 24.9xNo. of Companies5PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: ARE is expensive based on its Price-To-Earnings Ratio (60.5x) compared to the Global Health Care REITs industry average (24.9x).

Price to Earnings Ratio vs Fair Ratio

What is ARE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ARE PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio60.8x
Fair PE Ratio43.4x

Price-To-Earnings vs Fair Ratio: ARE is expensive based on its Price-To-Earnings Ratio (60.5x) compared to the estimated Fair Price-To-Earnings Ratio (43.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ARE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$97.80
US$120.54
+23.2%
8.0%US$144.00US$110.00n/a13
Dec ’25US$110.23
US$128.15
+16.3%
14.3%US$186.00US$112.00n/a13
Nov ’25US$110.86
US$133.08
+20.0%
13.0%US$186.00US$114.00n/a13
Oct ’25US$117.11
US$136.46
+16.5%
11.2%US$186.00US$125.00n/a13
Sep ’25US$119.57
US$137.62
+15.1%
11.5%US$186.00US$126.00n/a13
Aug ’25US$115.02
US$139.77
+21.5%
11.0%US$186.00US$126.00n/a13
Jul ’25US$115.81
US$142.77
+23.3%
10.1%US$186.00US$127.00n/a13
Jun ’25US$119.00
US$142.77
+20.0%
10.1%US$186.00US$127.00n/a13
May ’25US$116.79
US$143.08
+22.5%
10.0%US$186.00US$127.00n/a13
Apr ’25US$125.50
US$141.00
+12.4%
10.9%US$186.00US$118.00n/a13
Mar ’25US$124.27
US$140.92
+13.4%
11.0%US$186.00US$118.00n/a13
Feb ’25US$122.47
US$142.08
+16.0%
10.7%US$186.00US$118.00n/a13
Jan ’25US$126.77
US$135.67
+7.0%
13.9%US$186.00US$108.00n/a12
Dec ’24US$118.14
US$131.58
+11.4%
15.0%US$186.00US$108.00US$110.2312
Nov ’24US$92.90
US$136.50
+46.9%
15.9%US$186.00US$108.00US$110.8612
Oct ’24US$100.10
US$152.40
+52.2%
10.2%US$186.00US$132.00US$117.1110
Sep ’24US$116.95
US$157.40
+34.6%
9.2%US$186.00US$135.00US$119.5710
Aug ’24US$122.06
US$157.40
+29.0%
9.2%US$186.00US$137.00US$115.0210
Jul ’24US$113.49
US$161.67
+42.5%
9.7%US$186.00US$137.00US$115.819
Jun ’24US$112.37
US$162.11
+44.3%
9.7%US$186.00US$141.00US$119.009
May ’24US$121.82
US$173.44
+42.4%
10.7%US$198.00US$141.00US$116.799
Apr ’24US$125.59
US$174.30
+38.8%
9.8%US$198.00US$144.00US$125.5010
Mar ’24US$142.91
US$179.09
+25.3%
7.3%US$198.00US$145.00US$124.2711
Feb ’24US$163.27
US$176.73
+8.2%
6.9%US$198.00US$145.00US$122.4711
Jan ’24US$145.67
US$173.73
+19.3%
8.1%US$198.00US$141.00US$126.7711
Dec ’23US$154.87
US$174.18
+12.5%
7.9%US$198.00US$141.00US$118.1411

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 22:00
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Alexandria Real Estate Equities, Inc. is covered by 31 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David RodgersBaird
Wesley GolladayBaird
Ross SmotrichBarclays